Pegfilgrastim On Body Injector Nursing research (patient/Nurse questionnaire research)

Pegfilgrastim On Body Injector Nursing research (patient/Nurse questionnaire research) - Pegfilgrastim On Body Injector Nursing research (patient/Nurse questionnaire research)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050369

Enrollment

Registered

2023-02-20

Start date

2023-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients> 1) Patients who provide written consent for participation in this study 2) Breast cancer patients who underwent outpatient chemotherapy by their attending physician and who used a pegfilgrastim On Body Injector(G-Lasta subcutaneous injection 3.6 mg body pod) for the first time 3) Patients who are at least 20 years of age at the time of consent Nurses> Nurses who provide written consent for participation in this study

Exclusion criteria

Exclusion criteria: Patients> Patients deemed inappropriate by the principal investigator or subinvestigator Nurses> Principal investigator and co-investigator of this study

Design outcomes

Primary

Measure	Time frame
The usability, satisfaction of On Body Injector	—

Countries

Japan

Contacts

Public ContactTatsuhiko Hosaka

Kyowa Kirin Co., Ltd. Medical Affairs

hqmarinkensuit.sh@kyowakirin.com03-5205-7200

Outcome results